AstraZeneca

AstraZeneca, Moderna Therapeutics to develop pioneering messenger RNA Therapeutics

Friday, March 22, 2013 10:51 AM

AstraZeneca, a global biopharmaceutical company, has formed an exclusive agreement with Moderna Therapeutics, a Cambridge-Mass.-based biopharmaceutical company, to discover, develop and commercialize pioneering messenger RNA therapeutics for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer.

More... »

AstraZeneca to establish strategic R&D centers, cut or relocate 4,100 workers

Monday, March 18, 2013 02:12 PM

Global biopharmaceutical company AstraZeneca announced plans to invest in strategic R&D centers in the U.K., the U.S. and Sweden to improve pipeline productivity and to establish the company as a global leader in biopharmaceutical innovation.

More... »

AcelRx appoints Adrian Adams to board

Tuesday, February 12, 2013 08:00 AM

AcelRx Pharmaceuticals, a specialty pharmaceutical company focused on acute and breakthrough pain, has appointed Adrian Adams, CEO and president of Auxilium Pharmaceuticals, to its board of directors as chairman of the board.  

More... »

$262M Pan-European drug discovery platform launched

Friday, February 8, 2013 10:48 AM

The European Lead Factory, a novel platform for innovative drug discovery, was launched Feb. 7 by an international consortium of 30 partners. The partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates opportunities for the discovery of new medicines by providing public partners with an “industry-like” discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

More... »

AtheroNova names Shaw as new clinical affairs officer

Thursday, January 10, 2013 08:00 AM

AtheroNova, a biotech company focused on compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, has appointed Joan E. Shaw, MT (ASCP), SCC as senior director of clinical operations.

More... »

Cellular Dynamics, AstraZeneca partner on use of iPSC-derived human cells in drug discovery

Monday, January 7, 2013 02:16 PM

Cellular Dynamics International (CDI), a developer of next-generation stem cell technologies, signed a Center of Excellence agreement with global biopharmaceutical company AstraZeneca to accelerate the pace of drug discovery through the use of human induced pluripotent stem cell (iPSC) lines and tissue cells.

More... »

Isis, AstraZeneca form strategic alliance on RNA therapeutics for cancer

Wednesday, December 12, 2012 09:51 AM

Isis Pharmaceuticals of Carlsbad, Calif., and global biopharmaceutical company AstraZeneca have formed a strategic alliance for the discovery and development of novel generation antisense therapeutics against five cancer targets, which includes a license to develop and commercialize ISIS-STAT3Rx, a drug Isis is currently evaluating in an early clinical trial in patients with advanced lymphomas.

More... »

FDA approves Cometriq to treat rare type of thyroid cancer

Thursday, November 29, 2012 08:00 AM

The FDA has approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body.

More... »

NEOMED Institute aims to renew biopharmaceutical research in Québec

Tuesday, November 27, 2012 11:33 AM

AstraZeneca Canada and Pfizer Canada are forming a partnership with the Québec government to create the NEOMED Institute, a new kind of life sciences research center. A total of $100 million will be invested to establish and support the research center over five years.

More... »

Foundation Medicine, AstraZeneca collaborate on genomic profiling for targeted cancer therapies

Tuesday, November 13, 2012 09:23 AM

Foundation Medicine, a molecular information company based in Cambridge, Mass., has formed a multi-year collaboration with global biopharmaceutical company AstraZeneca to identify alterations found in cancer-related tumor genes that may predict a person's response or resistance to targeted medicines.

More... »